<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01563237</url>
  </required_header>
  <id_info>
    <org_study_id>INN004</org_study_id>
    <nct_id>NCT01563237</nct_id>
  </id_info>
  <brief_title>Safety and Performance of Miami InnFocus Drainage Implant (MIDI Arrow) Glaucoma Drainage Implant</brief_title>
  <official_title>Safety and Performance of Miami InnFocus Drainage Implant (MIDI Arrow) to Relieve Glaucoma Symptoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InnFocus Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InnFocus Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the safety and performance of the MIDI Arrow in patients suffering from glaucoma&#xD;
      that is inadequately controlled on maximum tolerated medical therapy with intraocular&#xD;
      pressure ≥ 18 mm Hg and ≤ 40 mm Hg&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a monocentric, non-randomized, single arm clinical study in which each patient&#xD;
      meeting the inclusion criteria and not excluded per the exclusion criteria will be implanted&#xD;
      with a MIDI Arrow in the anterior chamber of the eye. Patients will be followed for at least&#xD;
      24 months with an expected enrollment period of up to 24 months. Safety of the shunt will be&#xD;
      evaluated with indirect and direct microscopic evaluation of the implanted and non-implanted&#xD;
      eyes pre and post operatively, and at defined follow-up intervals for hypotony, inflammation,&#xD;
      infection, migration of the shunt, visual acuity, as well as a number of other defined&#xD;
      potential complications. The effectiveness of the shunt will be evaluated by measurement of&#xD;
      intraocular pressure at defined intervals.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Eyes With Study Success</measure>
    <time_frame>Months 6, 9, 12 and 24</time_frame>
    <description>The rate of success reflected sustained control of IOP over 24 Months from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IOP Change From Baseline</measure>
    <time_frame>At Day 1, Day 7, Week 3, Week 6, Month 3, Month 9, Month 12 and Month 24</time_frame>
    <description>Intraocular Pressure (IOP) change in studied eye compared to baseline value at all timepoints thru 24 Months.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Primary Open Angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>MIDI Arrow</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implantation of MIDI Arrow</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MIDI Arrow</intervention_name>
    <description>Implantation of MIDI Arrow</description>
    <arm_group_label>MIDI Arrow</arm_group_label>
    <other_name>Glaucoma drainage device implantation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patient, age 18 to 85 years, inclusive&#xD;
&#xD;
          2. Patient has primary open angle glaucoma that is inadequately controlled on tolerated&#xD;
             medical therapy with intraocular pressure greater than or equal to 18 mm Hg and less&#xD;
             than or equal to 40 mm Hg&#xD;
&#xD;
          3. Patient must have signed and dated the Informed Consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unwilling or unable to give informed consent or unable to return for scheduled&#xD;
             protocol visits.&#xD;
&#xD;
          2. Pregnant or nursing women.&#xD;
&#xD;
          3. No light perception.&#xD;
&#xD;
          4. Active iris neovascularization or active proliferative retinopathy.&#xD;
&#xD;
          5. Iridocorneal endothelial syndrome.&#xD;
&#xD;
          6. Epithelial or fibrous downgrowth.&#xD;
&#xD;
          7. Pseudoexfoliative glaucoma&#xD;
&#xD;
          8. Aphakia.&#xD;
&#xD;
          9. Vitreous in anterior chamber for which a vitrectomy is anticipated.&#xD;
&#xD;
         10. Corneal disease&#xD;
&#xD;
         11. Acute, chronic or recurrent uveitis.&#xD;
&#xD;
         12. Severe posterior blepharitis.&#xD;
&#xD;
         13. Unwilling to discontinue contact lens use after surgery.&#xD;
&#xD;
         14. Previous ophthalmic surgery, excluding phacoemulsification (cataract) surgery or&#xD;
             corneal refractive surgery.&#xD;
&#xD;
         15. Prior cataract surgery involving a conjunctival incision&#xD;
&#xD;
         16. Need for glaucoma surgery combined with other ocular procedures except for cataract&#xD;
             surgery or anticipated need for additional ocular surgery during the investigational&#xD;
             period.&#xD;
&#xD;
         17. Less than 0.1 (20/200) visual acuity in the non-test eye.&#xD;
&#xD;
         18. Infectious conjunctivitis, a narrow-angle glaucoma, endophthalmitis, orbital&#xD;
             cellulitis one, infection, severe dry eye, severe myopia, conjunctivitis fine.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isabelle M Riss, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique Mutualiste de Pessac, Pessac, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinique Mutualiste - Pavillon Ophtalmogique</name>
      <address>
        <city>Pessac</city>
        <zip>33600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 21, 2012</study_first_submitted>
  <study_first_submitted_qc>March 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2012</study_first_posted>
  <results_first_submitted>January 26, 2021</results_first_submitted>
  <results_first_submitted_qc>May 4, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 28, 2021</results_first_posted>
  <last_update_submitted>June 22, 2021</last_update_submitted>
  <last_update_submitted_qc>June 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Listing of Eyes under Study</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>First Studied Eye</title>
          <description>Patients suffering from glaucoma that is inadequately controlled on maximum tolerated medical therapy with intraocular pressure ≥ 18 mm Hg and ≤ 40 mm Hg.</description>
        </group>
        <group group_id="P2">
          <title>Second Studied Eye</title>
          <description>Patients suffering from glaucoma that is inadequately controlled on maximum tolerated medical therapy with intraocular pressure ≥ 18 mm Hg and ≤ 40 mm Hg.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Medical Reasons</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Intent-to-Treat (ITT) population included all enrolled subject who have signed the informed consent and attended the procedure visit to receive the assigned therapy under evaluation (MIDI Arrow).</population>
      <group_list>
        <group group_id="B1">
          <title>MIDI Arrow</title>
          <description>Implantation of MIDI Arrow (MicroShunt) in the anterior chamber of the eye in patients with primary open angle glaucoma (POAG)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="67"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.1" spread="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Eyes With Study Success</title>
        <description>The rate of success reflected sustained control of IOP over 24 Months from baseline</description>
        <time_frame>Months 6, 9, 12 and 24</time_frame>
        <population>The Intent-to-Treat (ITT) population included all enrolled eyes who have signed the informed consent and attended the procedure visit to receive the assigned therapy under evaluation (MIDI Arrow).</population>
        <group_list>
          <group group_id="O1">
            <title>Success With Respect to IOP</title>
            <description>The rates of success reflected sustained control of IOP</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Eyes With Study Success</title>
          <description>The rate of success reflected sustained control of IOP over 24 Months from baseline</description>
          <population>The Intent-to-Treat (ITT) population included all enrolled eyes who have signed the informed consent and attended the procedure visit to receive the assigned therapy under evaluation (MIDI Arrow).</population>
          <units>Implanted eyes</units>
          <param>Count of Units</param>
          <units_analyzed>Implanted eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Implanted eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IOP Change From Baseline</title>
        <description>Intraocular Pressure (IOP) change in studied eye compared to baseline value at all timepoints thru 24 Months.</description>
        <time_frame>At Day 1, Day 7, Week 3, Week 6, Month 3, Month 9, Month 12 and Month 24</time_frame>
        <population>The Intent-to-Treat (ITT) population included all enrolled subject who have signed the informed consent and attended the procedure visit to receive the assigned therapy under evaluation (MIDI Arrow).&#xD;
IOP data collected after glaucoma re-operation was censored for this analysis</population>
        <group_list>
          <group group_id="O1">
            <title>IOP Change From Baseline</title>
            <description>Change of IOP relative to the pre-operative value</description>
          </group>
        </group_list>
        <measure>
          <title>IOP Change From Baseline</title>
          <description>Intraocular Pressure (IOP) change in studied eye compared to baseline value at all timepoints thru 24 Months.</description>
          <population>The Intent-to-Treat (ITT) population included all enrolled subject who have signed the informed consent and attended the procedure visit to receive the assigned therapy under evaluation (MIDI Arrow).&#xD;
IOP data collected after glaucoma re-operation was censored for this analysis</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IOP at Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                  </count_list>
                </analyzed>
                <analyzed>
                  <units>eyes</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                  </count_list>
                </analyzed>
                <analyzed>
                  <units>eyes</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                  </count_list>
                </analyzed>
                <analyzed>
                  <units>eyes</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.9" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                  </count_list>
                </analyzed>
                <analyzed>
                  <units>eyes</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.2" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                  </count_list>
                </analyzed>
                <analyzed>
                  <units>eyes</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                  </count_list>
                </analyzed>
                <analyzed>
                  <units>eyes</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                  </count_list>
                </analyzed>
                <analyzed>
                  <units>eyes</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                  </count_list>
                </analyzed>
                <analyzed>
                  <units>eyes</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="66"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.4" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                  </count_list>
                </analyzed>
                <analyzed>
                  <units>eyes</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                  </count_list>
                </analyzed>
                <analyzed>
                  <units>eyes</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.2" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AEs) were reported for the duration of the study of 24 Months.</time_frame>
      <desc>Any untoward medical occurrence, unintended disease or injury or any untoward clinical signs (including an abnormal laboratory finding) affecting the study eye. Adverse Events were collected and reported per eye.</desc>
      <group_list>
        <group group_id="E1">
          <title>Study Eyes Selected to be Operated Within the Study</title>
          <description>Patients suffering from glaucoma that is inadequately controlled on maximum tolerated medical therapy with intraocular pressure ≥ 18 mm Hg and ≤ 40 mm Hg.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA v19</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Macular Degeneration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Macular Oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Visual Acuity Reduced</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Perforation Bile Duct</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Dacryocystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Conjunctival Filtering Bleb Leak</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA Coding">Intraocular Pressure Increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Gallbladder Operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Medical Device Repositioning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA v19</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Hyphaema</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Hypotony of eye</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Macular oedema</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Keratitis</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Ulcerative keratitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Eyelid ptosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Iris adhesions</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Conjunctivitis allergic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Retinopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Eyelid irritation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Allergic Keratitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Blepharitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Blepharospasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Choroidal detachment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Corneal irritation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Dacryostenosis acquired</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Eye Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Eye Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Lacrimal Disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Macular Degeneration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Narrow Anterior Chamber Angle</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Trichiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Drug Intolerance</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Perforation Bile Duct</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Dacryocystitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Conjunctival Abrasion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Conjunctival Filtering Bleb Leak</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Conjunctival Scar</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Procedural Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Suture Related Complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Intraocular pressure increased</sub_title>
                <counts group_id="E1" events="64" subjects_affected="39" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Intraocular Pressure Decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Visual Field Defect</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device Deployment Issue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Device Difficult To Use</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Device Occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Gallbladder Operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Medical Device Repositioning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Suture Removal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sharon Herbert, Associate Director of Clinical Operations</name_or_title>
      <organization>InnFocus, Inc.</organization>
      <phone>(415) 268-9059</phone>
      <email>sharon.herbert@santen.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

